Prostate cancer is primarily screened with the prostate-specific antigen (PSA) test. Recently, scientists have identified a set of protein biomarkers in urine that could detect prostate cancer presence and severity with remarkable precision. These biomarkers are expected to surpass the traditional PSA test in accuracy and offer a painless, non-invasive screening option¹⁰. Traditional PSA screening requires prostate biopsies following positive results, which can lead to psychological distress in some individuals for up to a year¹¹. As larger trials are conducted, these urine biomarkers promise to revolutionize prostate cancer screening by providing a more accurate and non-invasive tool for early detection and management.

References

10. Smelik M, et al. Cancer Res. Published online April 28, 2025. doi:10.1158/0008-5472.CAN-25-0269. 11. Lin K, et al. Rockville (MD): Agency for Healthcare Research and Quality (US); August 2008.